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Eight members of the Herpesviridae family commonly infect humans, and close to 100% of the adult
population is infected with at least one of these. The five that cause the most health concerns are: herpes
simplex virus (HSV) type 1 and 2, EpsteinBarr virus (EBV), cytomegalovirus (CMV), and varicella zoster
virus (VZV). In addition, there are human herpes virus (HHV) types 68. The review starts by introducing
possible viral strategies in general. The particular biology and host relationship of the various human
herpesviruses, including their pathology, are examined subsequently. Factors that contribute to the
maintenance of latency and reactivation of viral replication are discussed. There will be special reference
to how these viruses exploit and contribute to pathology in the oral cavity. Reactivation does not necessarily
imply clinical symptoms, as reflected in the asymptomatic shedding of EBV and CMV from oral mucosa.
The immune response and the level of viral output are both important to the consequences experienced.
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V
iral infections are generally recognized only when
they cause, or are suspected to cause, disease. The
more common scenario is most likely that viral
activity within a host does not result in any clinical
symptoms. This point has been demonstrated for a range
of potentially pathogenic viruses by finding a high
prevalence in healthy individuals (1, 2). It is important
to keep this in mind when exploring these agents and
their relationship with the host.
When symptoms do occur, they can be classified into
two groups. In the first group, symptoms are induced by
the virus for the particular purpose of advancing survival
and propagation. Typical examples are related to the
transfer of viral particles between individuals, as the
production of viral particles does not necessarily require
any noticeable damage to the host. Coughing, diarrhea,
and cold sore represent viral strategies that presumably
evolved for the purpose of contagion. In the second
group, symptoms are caused by the host response or
inadvertently by excess viral activity. When the immune
system reacts to foreign antigens, there will be collateral
damage. In some cases, however, the immune system
appears to overreact causing potentially more harm than
the virus itself. The response to certain strains of in-
fluenza virus is a possible example (3).
Viruses that have a long-term evolutionary relationship
with their host species are normally relatively benign.
These viruses rely on their hosts for replication, thus
evolution has designed the interaction to run smoothly.
It is generally not in the evolutionary interest of viruses
to kill or seriously maim their residence, as that would
impede further progress. Consequently, the more danger-
ous viruses are those with a recent zoonotic history; such
as HIV, SARS, Ebola, and avian influenza. The human
herpesviruses most likely have a long evolutionary history
of coevolution with our species. Thus, in a normal
environment, a healthy individual will rarely experience
their presence. The main exception being symptoms
related to viral transmission, such as chickenpox blisters
and herpes cold sores. The point of viral restraint is
particular relevant for herpesviruses due to their strategy
of latency. Latent viruses require a host who stays alive
and is healthy enough to interact with others.
There are two known examples of zoonotic herpesvirus
infections: the cercopithecine herpesvirus-1 and the
murine gamma herpesvirus. The former has a very high
fatality rate due to encephalomyelitis but is fortunately
rare (4); the latter is more common, one study suggests
a prevalence of 4.5% in a general population, but it is
relatively benign (5). This review focuses on the human
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herpesviruses. Although all eight subtypes are discussed,
occasionally the focus will be on one or two representa-
tive examples. This constraint is required for brevity but
also reflects limits of the present knowledge.
Viruses can be divided into three types relating to their
replicative strategies. Latency with occasional reemer-
gence is one. Viral latency should not be confused with
clinical latency, which is the incubation period in which
the virus is active, but symptoms have not yet appeared.
A second option is the ‘hit-and-run’ approach. Influenza
and the diarrhea causing norovirus are typical examples.
They display a rapid burst of replication but are sub-
sequently cleared from the system. They depend on their
hosts to shed large quantities of viral particles in the
hope that some will find the way to novel individuals. The
third option is the ‘slow-and-low’ tactic. These viruses
replicate continuously, but at a level sufficiently low not
to seriously damage their host or to provoke an immune
response of sufficient magnitude to risk expulsion. Hu-
man spumavirus (6) and torque teno virus (a member of
Circoviridae that infects humans) (7) appear to follow this
strategy. There is no clear-cut distinction between latency
and the slow-and-low approach. Even typically latent
viruses are not necessarily 100% dormant in-between
outbreaks, and in both cases viral activity will fluctuate.
Whether the virus follows a slow-and-low strategy, or has
cycles of reactivation, the number of viral particles
present is defined by the balance between viral prolifera-
tion and the capacity of the immune system for clearance.
If this balance moves too far in the direction of viral
particles, adverse consequences are likely to occur.
Torque teno viruses are not known to cause clinical
symptoms, yet they are present in the vast majority of
adults (7). The important question is why herpesviruses
occasionally are responsible for considerable pathogeni-
city. The problem is likely related to the way they are
designed for reactivation from latency; that is, rather than
a slow-and-low strategy, they have bursts of more
vigorous replicative activity. Understanding what regu-
lates the level of viral productivity, and the immune
response, may help us find strategies to deal with the
clinical problems.
Herpesviruses  biology and pathology
The human herpesviruses are large (typically 100200 nm),
enveloped (i.e. membrane-bound) viruses. They contain
double-stranded DNA genomes packed in an icosahedral
protein cage. The various genomes include 70200 pre-
dicted open reading frames, thus as to gene diversity they
are among the most complex human viruses. Moreover,
the number of open reading frames grossly underestimates
the true genomic output. For example, in the case of
cytomegalovirus (CMV), alternative splicing and optional
start codons give rise to more than 700 different viral
proteins (8). In addition, there are a large number of non-
coding RNAs based on the viral DNA that serve various
regulatory functions. In Fig. 1 is shown the lifecycle of
EpsteinBarr virus (EBV) as a typical example of a
herpesviral strategy.
Fig. 1. Schematic diagram of EBV replication cycle as an example of a typical herpesviral strategy. Modified from a figure in
Wikimedia Creative Commons, author Graham Colm.
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The large repertoire of herpes genes allows for an
intricate relationship with the host. Not only do these
viruses manipulate the cells they infect but also the
immune response.
The alpha subfamily (varicella zoster virus [VZV] and
herpes simplex virus [HSV]-1 and -2) primarily target
neurons for long-term residency, but they also replicate in
epithelia, which is essential for efficient transmission
through skin or mucosa. The others (beta and gamma
subfamilies) prefer various subsets of leukocytes, but
most of them can also infect epithelial cells. Cell tropism
is determined by the presence of cell surface receptors,
as well as by whether the intracellular conditions are
supportive for viral activity. In general, the replication
takes place within the nucleus. In some host cells, gene
products based on latency-associated transcripts accu-
mulate, which lead to a period of latency. If transcription
is shifted to lytic products, novel viral particles are
produced, which typically leads to the death of the cell.
The reactivation is traditionally associated with malaise
but does not necessarily lead to any notable symptoms.
Below are outlined the main clinical outcomes for the
various viral types. An overview of the viruses is shown in
Table 1. A review of the management of pathology has
been recently published (9).
Herpes simplex virus
HSV-1 is primarily associated with blisters, referred to as
cold sores, or herpes labialis, on the lips. The HSV-2 is
associated with related genital sores or blisters; however,
both viruses can cause lesions at either site. In fact, the
HSV-1 is today the most common form found in genital
herpes (10). Sores typically occur a few days after the
primary infection, and reappear more or less regularly
later in life for a substantial percentage of those infected.
The blisters contain abundant viral particles and pre-
sumably represent a main strategy for viral transmission.
Host factors, such as the intensity of the immune res-
ponse, may worsen the symptoms. The viruses take life-
time residency in nerve cells and are transported to the
mucosa along axons. Over time, the episodes tend to
diminish in frequency and severity. The genital form is
less likely to cause recurrent blisters, but the virus may
still be shed through the mucosa.
The mucosal sores are the common sign of an active
infection, but HSV can also produce cutaneous lesions,
particularly around the nails of fingers and toes, a
Table 1. Key properties of human herpesviruses
Trivial name
and acronym Formal name Type
Oral
affection
Other
pathology
Primary
target cells
Main sites
of latency
Herpes simplex
virus-1 (HSV-1)
Human
herpesvirus 1
Alpha Cold sores
(herpes ulcers)
Genital ulcers, related
skin lesions, keratitis,
encephalitis, meningitis
Mucoepithelia Sensory and
cranial nerve
ganglia
Herpes simplex
virus-2 (HSV-2)
Human
herpesvirus 2
Alpha Cold sores
(herpes ulcers)
Genital ulcers, as
HSV-1 but more rare
Mucoepithelia Sensory and
cranial nerve
ganglia
Varicella zoster
virus (VZV)
Human
herpesvirus 3
Alpha Possible oral
manifestation of
chicken pox and
herpes zoster
Chicken pox, herpes
zoster
Mucoepithelia Sensory and
cranial nerve
ganglia
EpsteinBarr
virus (EBV)
Human
herpesvirus 4
Gamma Hairy leukoplakia,
periodontitis,
nasopharyngeal
carcinoma
Mononucleosis,
lymphoma
Epithelial and
B-cells
Memory B-cells
Cytomegalovirus
(CMV)
Human
herpesvirus 5
Beta Periodontitis? Mononucleosis Monocytes,
lymphocytes
and epithelia
Monocytes,
lymphocytes
Roseola virus
(HHV-6)
Human
herpesvirus
6A and 6B
Beta Roseola in infants T-cells Various
leukocytes
Roseola virus
(HHV-7)
Human
herpesvirus 7
Beta Roseola in infants T-cells T-cells, epithelia
Kaposi’s sarcoma-
associated virus
(HHV-8)
Human
herpesvirus 8
Gamma Kaposi’s sarcoma Probably
lymphocytes
and epithelia
B-cells
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condition referred to as herpetic whitlow (11). In the
absence of gloves, it used to be a common problem for
dental workers (12). HSV can also reach the eyes causing
keratitis, which may lead to blindness (13). Based on their
affinity for neurons and epithelial cells they may attack
the brain resulting in encephalitis or meningitis (14).
Whereas the mucosal and cutaneous symptoms have
obvious significance for viral transmission, the activity
in the brain appears to be an incongruity. It may reflect
stress factors in the host causing demoted immune
surveillance.
Varicella zoster virus
The VZV is related to the HSV both in evolutionary
terms and in cell tropism and, as might be expected, the
clinical picture has shared characteristics. The primary
infection with VZV normally results in chickenpox. The
disease is typically accompanied by malaise, such as low-
grade fever, nausea, aching muscles, and headache. It
starts with a vesicular, itchy rash that primarily affects the
trunk and the head. VZV may also form ulcers in the oral
cavity.
The clinical picture is somewhat different if the virus is
reactivated later in life. The disease is then referred to as
herpes zoster or shingles. In both cases, the virus causes
skin rash with blistering, but in the recurrent form
typically on a more limited area of the body. Apparently,
the immune system prevents a more global viral activity
but is unable to avert a limited number of nerve cells from
producing virus that are brought to the terminating area
of their axons; that is, to a particular dermatome (15).
As in the case with HSV, VZV is also known to cause
encephalitis.
EpsteinBarr virus and cytomegalovirus
EBV and CMV belong to respectively the gamma and
beta subfamily of Herpesviridae, yet the clinical picture is
related. EBV primarily infects B-cells, whereas CMV is
designed to enter monocytes besides lymphocytes. Both
of them also infect epithelial cells. They cause mono-
nucleosis, or mononucleosis-like symptoms, although the
condition is more commonly associated with EBV. The
illness is most prevalent in adolescents, where it is
referred to as kissing disease based on a typical route of
transmission. The condition manifests itself with fever,
sore throat, fatigue, and swollen lymph nodes. Presum-
ably, it is a consequence of the inability of the immune
system to handle the virus in an appropriate fashion at
this stage of life. Those who first encounter these viruses
as infants rarely develop symptoms.
Congenital infection with CMV is one of the leading
viral causes of birth defects (16). EBV, however, is known
to be tumorigenic. It is associated with various forms of
lymphomas as well as with nasopharyngeal carcinomas.
In immunocompromised individuals, particularly in as-
sociation with AIDS, the virus may cause oral hairy
leukoplakia, a condition characterized by white patches
typically on the lateral surface of the tongue (17).
If the host is unable to keep these viruses at bay, they
may also contribute to periodontitis (18, 19). This point
has been indicated by the successful treatment of a patient,
suffering from severe periodontitis, with valacyclovir (20).
The patient did not respond to traditional treatment, and
prior to the use of valacyclovir there were exceptionally
high levels of EBV in affected periodontal pockets, which
disappeared following 10 days of medication.
Human herpesvirus -6, -7 and -8
Human herpesviruses (HHVs)-68 were discovered rela-
tively late. As with the other herpesviruses, at least types 6
and 7, often referred to as roseola viruses, can form skin
lesions; in this case referred to as exanthema subitum or
roseola infantum (21). The condition is usually seen only in
infants less than 2 years of age. The onset is characterized
by sudden high fever. As the fever subsides, a red rash
appears. It usually begins on the trunk, but spreads to the
legs and neck. Although only some 30% develop symp-
toms, the vast majority of infants 2 to 4 years old harbor
the virus (21).
HHV-8 is associated with Kaposi’s sarcoma, a form of
cancer that became known through its diagnosis in
patients with AIDS (22). The virus is common in sub-
Saharan Africa but rarer in other parts of the world.
Presumably, the majority of those infected show no
symptoms.
Viral strategy
An act of balance
The emerging picture, of the natural biology of herpes-
viruses, is a primary infection with mild or no symptoms,
and a highly successful establishment of a long-term
relationship with the host. Viral activity may be asso-
ciated with lesions either in the skin, the oral cavity, or
genital region as a means of transmitting viral particles to
novel hosts. The normal course of hostviral relation-
ship implies a well-regulated viremia and thus limited
malaise. However, certain factors cause this evolutionary-
designed, benign relationship to fault.
For one, the design is tuned to a ubiquitous presence of
viruses in the population, and the acquisition of virus at
an early age. As such, they may be referred to as part of
a normal, microbiotic flora; although in ancient times
all subtypes were probably not present in all human
subpopulations. An elevated level of hygiene in indus-
trialized societies restricts this early transmission. When
people are affected at a later stage in life, the immune
system has taken on a somewhat different quality. The
resulting misbalance of viral activity may cause diseases,
of which mononucleosis presumably is a typical example.
Bjørn Grinde
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Not only do these patients experience more malaise than
infected infants but they are also at higher risk for
recurrent problems later in life (23).
The balance between viral activity and immune sup-
pression may also be compromised if the quality of
immune surveillance is reduced, particularly in cases of a
depressed T-cell immune function. This is a problem for
people who suffer from innate or acquired immune
deficiency, the latter exemplified by AIDS. Patients who
receive organ transplants are generally given immuno-
suppressant medicines that produce a related effect (24).
Physical or psychological stress (25), and the reduction
in bodily functions associated with aging (26), may be
sufficient to disturb the delicate balance between viral
activity and immune response.
In addition to the problems related to increased viral
load, some herpesvirus, notably EBV and HHV-8, are
associated with cancer. Most viruses that reproduce in the
nucleus require the presence of host factors associated
with replication and transcription; thus viral replication
is, to a lesser or greater extent, dependent on mitotic
activation of the cell they inhabit. Moreover, the herpes-
viruses manufacture gene products aimed at helping
the cell survive; an effect that is at least partly due to
microRNAs produced from the viral genome and acting
as regulators of cellular genes (27). EBV in particular
produces factors in the early phase of infection that lead
to the immortalization of B-lymphocytes (24). This
strategy of stimulating the cell requires a fine balance.
If the physiology of the cell tips too far in the direction of
growth, the result may be uncontrolled cell division, that
is, cancer. The problem is rarely an issue for viruses that
target neurons, as these cells are more permanently left in
a non-replicative state. However, the lymphocytes and
epithelial cells are more tuned toward replication; and
consequently more in danger of having the balance meant
to control cell growth overthrown. It should be noted that
compared to the prevalence of the herpesviruses, this
unfortunate event (for both host and virus) is rare.
The role of the oral cavity
The oral cavity plays a vital role in the transmission of a
large range of viruses including most human herpes-
viruses. The crucial issue seems to be that the oral mucosa
has certain preferred features compared to skin or genital
mucosa: The mouth offers more efficient transmission
because the virus can be dispersed in aerosols, either
released by normal breathing, but more efficiently pro-
duced upon coughing or spitting. Moreover, as enveloped
viruses, the herpes family requires moisture for survival.
The blisters on the skin serve the purpose as long as
they are watery, but the virus relies on skin-to-skin contact
with another person, or immediate contact between
objects touched by the infected person and the next
host. The occurrence of kissing and food sharing by
mouth contribute further to the role of the human mouth
in the transmission of pathogens. Biting is still considered
to be a relevant risk factor in the transfer of viruses from
other primates (28).
Viruses such as EBV and CMV are common in the oral
mucosa (18, 19), but also HSV, HHV-6 and HHV-7 can be
shed from a healthy oral mucosa (24). Apparently, all
herpesviruses have evolved the capacity to access the oral
cavity. EBV, CMV, and HHV-68 replicate in epithelium
cells or various leukocytes where the latter can infiltrate
the mucosa. VZV, and HSV-1 and -2 are latent in neurons,
but the viral particles are transported via axons to mucosa
where the virus may continue replicating in epithelial cells.
It should be noted that using the mouth as part of the
strategy for viral contagion does not require the forma-
tion of sores, blisters, or other visible changes in the
mucosa. However, clinical symptoms associated with the
mucosa generally imply a higher abundance of viral
particles, and thus a boosted chance of transmission.
Latency and reactivation
Features associated with latency and reactivation
Reactivation is a dangerous option for the virus. An active
replication will tend to induce various host mechanisms,
involving either the immune system or internal signaling
in the cell, leading to the death of the infected cell. For
every viral genome that successfully produces infective
progeny, several viruses probably initiate this process, but
fail at some point along the way.
In order to establish latency, the viral genome is
circularized to form an episomal DNA element packed
in histones (29). For lytic activation to occur, the genome
must be linearized (30). During latency, the viral DNA is
copied by cellular DNA polymerases, along with the
chromosomes, preferably when the cell engages in mitosis.
This contrasts with lytic replication in which the viral
DNA polymerase is engaged, reflecting a viral takeover
of the cell. For latency, the virus relies on the host’s epi-
genetic mechanisms for the silencing of viral genes, such
as packaging of the DNA in particular types of histones
and specific methylation programs (30). Presumably it is
safer to keep the production of viral proteins to a mini-
mum during latency in order to avoid immune surveil-
lance; but at the same time it is important for the virus to
be copied in order to maintain long-term presence, as
some of the daughter cells will eventually die.
The viral genome is not completely silenced. Latent
EBV, for example, expresses a small portion of its genes
(31). The virus exhibits three different latency programs,
each comprising a limited and distinct set of viral
proteins and RNAs (32, 33). Upon infecting a resting
B-cell, the virus starts with the more comprehensive
latency III program. The resulting proteins induce the
B-cell to proliferate. The virus subsequently gradually
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shuts off genes, entering latency II and eventually latency
I. In latency I, only one protein and some non-coding
RNAs are expressed. The protein, EBNA-1, binds to a
replication origin in the viral genome and is instrumental
in securing synthesis of DNA when the host cell divides.
Lytic gene products are also produced in three con-
secutive stages: immediate-early, early, and late (23). The
primary role of the immediate-early lytic products is to
function as transactivators, enhancing the expression of
later lytic genes. The early lytic products take on more
diverse functions, such as replication, metabolism, and
blockade of antigen processing. The late lytic products
are typically proteins with structural roles, including the
units of the capsid and glycoproteins that are incorpo-
rated in the viral envelope. Other late gene products, such
as BCRF1, help EBV evade the immune system. The
actual changes in both viral and host cell transcription
and translation over the various stages of viral latency
and reactivation are highly complex, as demonstrated
with various functional genomics studies on CMV (34).
Herpesviruses, being enveloped, normally bud from the
cell membrane, which implies that lysis of the cell is not
required. However, the takeover necessary for running
active production of viral particles in epithelial cells or
leukocytes typically results in cell death.
In the case of HSVs, much of our knowledge of the
molecular control of latency comes from studies with
virus in cultured neuronal cells (30). Here axonal trans-
port plays an important role. If the virus first enters at a
distant spot on an axon, as compared to closer to the cell
body, the situation favors latency. The explanation may
be inefficient axonal transport of virion-associated reg-
ulatory factors, such as the HSV lytic initiator protein
VP16 (35). The protein is released from the viral particle
upon entry, and subsequently requires independent trans-
port to the nucleus in order to initiate the replicative
program. Thus, if the distance to the cell body is large,
less VP16 will reach the nucleus, and the onset of viral
productivity is compromised. Later on, other factors may
initiate de novo synthesis of VP16 in the nucleus thus
causing reactivation.
Viral impact on immune surveillance
Herpesviruses are known for their ability to establish
lifelong infections. In order to do so they require a
strategy for immune evasion, consequently the viruses
have evolved a variety of ways to manipulate the immune
system of the host. One typical example is based on
molecular mimicry. Most of the viruses encode homologs
of cellular interleukins (IL), chemokines, or chemokine
receptors (36). The EBV gene BCRF1, for example,
encodes a viral homolog of human IL-10 (37). The viral
version of IL-10 impairs NK cell mediated killing of
infected B-cells, interferes with CD4 T-cell activity, and
modulates cellular cytokine response. Another strategy
for immune evasion is to reduce the presentation of
viral antigens via the major histocompatibility complex
(MHC) of infected cells (38). Some viruses simply
downregulate or inhibit the display of both MHC class
I and II molecules. The EBV-encoded BNLF2a gene
reduces antigen presentation, and consequently recogni-
tion by CD8 T-cells, in newly infected cells (37).
The manipulation of the immune system offers the
reactivated virus at least partial relief from immune
surveillance. It is, however, a feature that increases the
risk of the balance tipping toward excessive viral produc-
tivity, which is not in the interest of the virus as it can
lead to death or serious disability of the host. Evolution
apparently has balanced this possibility, leading to a
situation where the viral activity in a normal host is
limited to a considerable extent by immune surveillance.
The point is substantiated by the observation that
compromised immunity, as in the case of patients receiv-
ing immune suppressants, often lead to a drastic increase
in viral activity (24).
Other data suggest that herpesviruses can in fact form
a symbiotic relationship with their hosts. In a mouse
model, it has been shown that the systemic activation of
macrophages and the prolonged production of inter-
feron-gamma initiated by herpesviral infections protect
against subsequent disease caused by the highly patho-
genic bacteria Listeria monocytogenes and Yersinia pestis
(39). The suggestion of symbiosis is plausible as it is
obviously not in the interest of the virus to have their host
succumb to other infections.
External factors involved in reactivation
In animal models, and most likely in humans as well,
reactivation of various herpesviruses can be induced by
local trauma (e.g. in the form of surgery) or systemic
stress. An example of the latter is to elevate the body
temperature of mice to 438C for 10 min (40). The
appearance of HSV cold sores correlates with a wide
range of stressors, including mental tension, fatigue, and
exposure to bright light (41). More than 100 years ago it
was shown that applying trauma to a nerve, for example in
connection with the treatment of chronic pain, can lead to
an outbreak of herpes in the dermatome associated with
the nerve (30).
Other cell stressors, such as transient interruption
of protein synthesis or hypoxia, are sufficient to induce
viral activity  an effect that may be mediated by the
disruption of mTOR kinase activity (42). This enzyme
has a central role in responding to nutritional or to stress-
related cellular events by impacting on mRNA transla-
tion. Apparently, in the case of HSV, it is sufficient to
inhibit mTOR (by chemical means) in the distal part of
an axon; a signal causing viral reactivation is then sent to
the cell body harboring the viral episome. Presumably,
a skin trauma affecting the nerve endings of infected
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neurons may cause a similar reactivation. In order to
maintain latency, the neuron must be functional, active,
and healthy. Similar to rats, the virus prepares to ‘leave
the ship’ if it is likely to ‘sink’.
In cell culture systems, it is also possible to induce
reactivation by interfering chemically in ways that impact
on gene activity, using compounds that for example block
histone methylation or appropriately designed interfering
RNAs (30). The question is what factors cause a similar
impact on gene expression in vivo. As to HSV, it is known
that environmental triggers such as emotional stress,
fever, UV exposure, hormonal changes, dental surgery,
and cranial trauma can cause activation (30); but it is not
known whether these stimuli act directly on the infected
neuron, or indirectly by means of bodily functions.
One possible mechanism for the effect of mental
stressors is via virus-specific CD8 T-cells. These cells
are often found in association with infected neurons,
sometimes connected to the neuron via immunological
synapses. They produce interferons and related factors
that presumably contribute to the maintenance of latency
and at the same time help the neuron survive (43). Both
mental and physical stressors are known to influence the
activity of CD8 T-cells through the release of neuroen-
docrine factors, a mechanism that may link the control
of HSV latency to activity in the sympathetic nervous
system (44). In the case of EBV, the latent virus harbored
in B-cells can be reactivated in vitro by stimulating B-cell
receptors, suggesting that reactivation in vivo may occur
when the infected B-cell responds to unrelated infections
(23). The point may help explain why reactivation of EBV
occasionally appears as a secondary infection.
The aging immune system is no longer able to control
the virus efficiently leading to a more chronic, slow-and-
low rather than latent type of infection (45). A range of
deteriorative immunological changes are expected to
correlate with aging, but it is not known exactly what
causes the concomitant increase in herpesvirus activity. In
fact, the stress associated with space flight is sufficient to
cause reactivation of latent herpesviruses, presumably by
downregulating cellular immunity (46); which suggests
that even a minor decline, or change, in immunological
function may be enough. This point is also reflected in
the observation that it makes considerable difference
whether the individual is first infected as an infant or in
puberty, as exemplified by the case of EBV and mono-
nucleosis. One probable cause of an increase in EBV
activity late in life is actually a prior increase in CMV
activity. The latter event results in an expansion of
senescent CD8 T-cells which lack CD28, but are
directed at CMV epitopes; an expansion that has been
suggested to restrict immune response to other pathogens
including EBV (47). In other words, when CMV (and
possibly other herpesviruses) gradually produces more
viral proteins and particles, the concomitant attempt of
counteracting the situation by an aging immune system
can demote the capacity to fight these viruses.
Concluding remarks
We have considerable knowledge of the various pathways
of molecular signaling that can lead to reactivation, and
we have empirical information of environmental triggers
doing the same. What we do not know is which molecular
or cellular pathways the environmental factors use. It
could be through some of the options outlined by, mostly
in vitro, experiments; or it could be novel mechanisms.
Apparently, viral activity depends on a delicate balance of
constraining and activating factors. Minor disturbances
that upset this balance seem sufficient to lead the virus
toward production of progeny, and presumably this dis-
turbance can result from a variety of effectors.
In most cases, reactivation does not lead to serious
disease. It is sufficient for the virus to be shed in the oral
cavity, and even HSV appears in the saliva in the absence
of sores (48). Then again the level of viral activity most
likely correlates with clinical symptoms. Innate and
acquired host factors will affect the balance between viral
activity and immune surveillance, making some people
more susceptible to problematic infections than others.
In this context, it should be mentioned that we tend to
attribute guilt by association. If symptoms correlate with
the detection of virus, we tend to assume that the virus
is responsible. This may lead to a faulty diagnosis and
suboptimal treatment. The herpesviruses are likely to be
reactivated as a consequence of a variety of conditions,
but they are not necessarily involved in the underlying
etiology. Due to their almost ubiquitous presence and
ease of activation, clinical findings and epidemiology may
suggest a causative role, even if the viruses are mere
opportunists.
The delicate balance between latency and reactivation
is designed by evolution. In a normal host, experiencing
the normal interaction with the virus, the process is tuned
to a long-term relationship that does not cause undue
harm. However, if environmental factors upset this
balance, or if the host for whatever reason is immuno-
compromised, the virus may inadvertently cause disease.
One might speculate that the optimal strategy for
counteracting disease is to encourage early life exposure
to herpesviruses. For the average person, infant inocula-
tion with EBV and CMV may be beneficial, but the
strategy does imply a risk for disease in rare individuals.
Moreover, we live to an age where it is expected that the
immune system has reduced potential, and occasionally
we need to subdue the system in connection with various
treatments. Thus, harmful consequences of these viruses
are likely to occur at some point in life. One alternative is
vaccines. We do have a vaccine for VZV, and vaccines are
currently under development for HSV (49), EBV (50),
and CMV (51). The more commonly used alternative at
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the present is medication. Fortunately, we have a con-
siderable pharmaceutical arsenal to fight these viruses
(9), unfortunately these medicines are unlikely to rid the
body of virus.
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